Key Highlights

• Late-Breaking Selection: Tenax Therapeutics (NASDAQ: TENX) will present Phase 3 LEVEL trial data at a Late-Breaking Clinical Science session at ESC Congress 2026 in Munich.

• Oral Heart Failure Candidate: TNX-103 is an oral formulation of levosimendan, a therapy currently used intravenously in acute heart failure.

• Topline Data Expected in August: Results from the LEVEL study are anticipated in August 2026, ahead of what could be a pivotal readout for the company.

Tenax Therapeutics (NASDAQ: TENX) announced that Phase 3 data from its LEVEL trial for TNX-103, an oral formulation of levosimendan, has been selected for a Late-Breaking Clinical Science session at the European Society of Cardiology Congress 2026 in Munich, scheduled for August 28-31.

The ESC Congress is one of the largest and most closely followed cardiovascular medicine conferences in the world. Selection for a Late-Breaking session indicates that the scientific committee views the data as carrying meaningful potential relevance to clinical practice.

Levosimendan is an inotrope already established in acute heart failure care, but its use has historically been limited to intravenous administration in hospital settings. TNX-103 aims to make the therapy available in oral form, which could allow for outpatient maintenance treatment that current IV-only options cannot support.

Heart failure patients who become refractory to standard therapies represent a population with very limited treatment alternatives. An oral levosimendan option, if proven effective, would give physicians a new tool for managing these patients outside of the hospital.

Tenax Therapeutics has stated that topline results from the LEVEL study are expected in August 2026, timed closely with the ESC presentation. The company is currently finalizing database lock and completing statistical analyses ahead of the data release.

Presenting pivotal trial results at a major medical conference alongside peer-reviewed publication is a common strategy for cardiovascular drug developers. It allows a company to reach both the scientific community and the investment community with a single, coordinated data release.

The scale of the addressable heart failure population makes any positive signal from the LEVEL trial a potentially significant event for Tenax Therapeutics. Chronic heart failure affects millions of patients globally, and treatments that can be administered outside a hospital setting carry commercial appeal for payers and providers alike.

Investors in clinical-stage cardiovascular names often treat conference selection itself as an early positive indicator, since major congresses tend to prioritize data with clear potential to influence treatment guidelines. That said, the ultimate market reaction will depend on the actual efficacy and safety profile disclosed in August.

Should the LEVEL trial produce a favorable outcome, TNX-103 could position Tenax Therapeutics as one of the few companies advancing an oral levosimendan option toward regulatory review. The company has not yet detailed its post-data regulatory filing timeline.

The next several weeks leading into the ESC Congress are likely to be a period of heightened attention for Tenax Therapeutics shareholders as the company finalizes its data package.

 

This article is for informational purposes only and does not constitute financial, investment, or trading advice. Readers should conduct their own research and consult a licensed financial advisor before making any investment decisions. Past performance and regulatory or clinical milestones are not guarantees of future results.